JPRN-UMIN000015996已完成未知
Investigation of clinical efficacy of Enzalutamide and its predictive factors in CRPC patients - Efficacy of Enzalutamide in CRPC patients
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 95years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1)Severe cardiac function disorders, hepatic function disorders, renal function disorders, infectious disease or hematopoietic disorders 2)Hypersensitivity to study medication 3)History of seizure or any condition that may predispose to seizure 4)Age <20 years 5)History of treatment with Enzalutamide, Abiraterone or chemotherapy 6)Patients whom the investigator judges inappropriate for the study
研究者
相似试验
尚未招募
2 期
The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancernon-muscle invasive bladder cancerJPRN-UMIN000026520rology department of Tsukuba University Hospital10
进行中（未招募）
1 期
Enzalutamide Treatment of Metastatic Castration-Resistant Prostate Cancer Patients after Abiraterone AcetateEUCTR2013-002271-17-DEAstellas Pharma Europe B.V.200
已完成
2 期
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerAdvanced, Androgen Receptor Positive Triple Negative Breast CancerNCT01889238Pfizer118
已完成
不适用
The efficacy and safety of enzalutamide for castrate-resistant prostate cancer patient showing disease progression after or during chemotherapy including docetaxel.Castrate-resistant prostate cancerJPRN-UMIN000023627Kumamoto University20
进行中（未招募）
不适用
A trial of the combination treatment enzalutamide and AZD5363 for patients with advanced prostate cancer.EUCTR2013-004091-34-GBThe Royal Marsden NHS Foundation Trust136